This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Clinical Experience -
Comparisons of voided urine cytology, nuclear matrix
protein-22 and bladder tumor associated antigen tests for bladder cancer
of geriatric male patients in Taiwan, China
Ke-Hung Tsui1, Shao-Ming
Chen2, Ta-Ming Wang3, Horng-Heng
Juang4, Chien-Lun Chen3, Guang-Huan
Sun5, Phei-Lang Chang3
1Department of Nursing, Chang Gung Institute of Technology, Kwei Shan, Taoyuan 333, Taiwan, China
2Department of Urology, Taipei City Hospital, Heping Campus, Taipei 100, Taiwan, China
3Department of Geriatric Urology, Chang Gung Bioinformatics Center, Chang Gung Memorial Hospital, Kwei Shan,
TaoYuan 333, Taiwan, China
4Department of Anatomy, College of Medicine, Chang Gung University, Taoyuan 332, Taiwan, China
5Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taibei 114,
Taiwan, China
Abstract
Aim: To compare the results of bladder tumor associated antigen (BTA TRAK), nuclear matrix protein 22 (NMP 22)
and voided urine cytology (VUC) in detecting bladder cancer.
Methods: A total of 135 elderly male and 50 healthy
volunteers enrolled in this study were classified into three groups: (i) 93 patients with bladder cancer; (ii) 42 patients
with urinary benign conditions; and (iii) 50 healthy volunteers. BTA TRAK and NMP 22 kits were used to detect
bladder cancer. Voided urine cytology was used to compare the sensitivity and specificity of the screening
tests. Results: The sensitivity and specificity of cytology, BTA TRAK and NMP 22 were 24% and 97%, 51% and 73%,
78% and 73%, respectively. The level of NMP 22 increased with tumor grading. The BTA TRAK kit has the lowest
sensitivity among the screening tests. The NMP 22 with the best sensitivity can be an adjunct to cytology for
evaluating bladder cancer. Conclusion:
The NMP 22 test has a better correlation with the grading of the bladder
cancer than BTA TRAK. As cytology units are typically not available in hospitals or in outpatient clinics, NMP 22
might be a promising tool for screening bladder
cancer. (Asian J Androl 2007 Sep; 9: 711_715)
Keywords: bladder neoplasm; cytology; bladder tumor associated antigen; nuclear matrix protein 22
Correspondence to: Dr Phei-Lang Chang, Department of Geriatric Urology, Chang Gung Memorial Hospital, 5 Fu-Shing Street,
Kweishan, Taoyuan 333, Taiwan, China.
Tel: +886-3328-1200-2137 Fax: +886-3327-4541
E-mail: khtsui@yahoo.com
Received 2006-04-18 Accepted 2006-06-05
DOI: 10.1111/j.1745-7262.2007.00218.x
1 Introduction
Bladder cancer is a common cancer in Taiwan, China
[1]. It is the fourth most common cancer in men and
the eighth in women [2]. Aging male have a high
incidence of bladder cancer which is up to five times more
common than that in women and has prompted many urologists to screen this population more vigorously than
others. Because bladder cancer appears to be more
prevalent and more insidious in this population, testing the
efficacy of bladder cancer biomarkers in geriatric patients
is imperative [3].
Cystoscopy and cytology are routinely used for evaluation of bladder cancer. Previously, bladder
cancer was only detected by cytology and cytoscopy. Both
techniques have particular limitations: cytology has low
sensitivity, and cystoscopy is a surgical intervention
causing patient discomfort. There has been increasing
interest in the development of more accurate tests ranging
from flow cytometry to monoclonal antibodies and cell
surface antigens. Portable screening tests have been
developed to detect bladder cancer, and among them, two
portable non-invasive diagnostic tools, bladder tumor
associated antigen (BTA TRAK) [4] and nuclear matrix
protein 22 (NMP 22) [5] are simple and rapid procedures.
Bladder tumor associated antigen detected by the BTA
TRAK assay has been identified as a human complement
factor H-related protein (hCFHrp) [6]. It is similar, but
not identical, to the human complement factor H (hCFH),
which plays an important role in the complement system.
BTA TRAK is produced by bladder tumor cells in cell
cultures and is shed into urine of bladder cancer patients.
It can be detected using a BTA TRAK assay. NMP 22 is
an RNA protein network forming the structural
framework of the nucleus [7]. The matrix provides the
functional organization of deoxyribonucleic acid. The
proteins bound to the RNA in the matrix are nuclear matrix
proteins (NMP). These NMP differ between normal and
cancer cell lines. NMP 22 is released from the cell
during cell death. Both BTA TRAK and NMP 22 levels are
measured in freshly voided spot urine.
By applying an immunoassay principle, BTA TRAK and NMP 22 test kits provide results in a few minutes
and in 1 day, respectively. The present study compares
the results of the BTA TRAK test and the NMP 22 test in
detecting bladder cancer, using a variety of controls, in
relation to urinary cytology. The final diagnosis of
bladder cancer is confirmed by cytoscopy (voided urine
cytology [VUC]) and biopsy.
2 Materials and methods
All studies were approved by the Institutional
Review Board for the Protection of Human Subjects and
informed consent was obtained from each patient. A
total of 135 elderly male and 50 healthy volunteers (range:
60_86 years; mean age: 68 years) were enrolled in this
prospective study. Patients were accepted between April
2001 and November 2003. The subjects were classified
into three groups: (i) 93 elderly patients with bladder
cancer; (ii) 42 patients with urinary benign conditions;
and (iii) 50 healthy volunteers. Using intravenous
pyelography and ultrasound, all patients with hematuria
produced negative urinary tract results. In the study, 45
and 48 patients were examined by BTA TRAK and NMP 22, respectively. No patient management decisions were
based on both test results. The thresholds for BTA TRAK
and NMP 22 corresponding to 97% specificity were 12 U/mL
and 10 U/mL, respectively. The two screening tests were
performed by two doctors. The cytology was examined
by one pathologist only. Malignant transitional cell is
defined by alterations of the ratio of cytoplasm and
nucleus and morphology.
A diagnosis of bladder malignancy was made when a
bladder tumor was observed during cystoscopic
evaluation and was confirmed by a positive histology result
from a biopsy sample. Tumors were graded according
to the World Health Organization (WHO) grading system
[8]: grade I (low), slight anaplasia; grade II (medium),
moderate anaplasia; and grade III (high), severe
anaplasia. Sensitivity is defined as the ratio of the number of true
positive test results to the number of confirmed bladder
cancer samples tested. Specificity is defined as the ratio
of the number of true negative test results to the number
of non-bladder cancer samples tested. Exact 95%
confidence intervals (CI) indicate the precisions of
sensitivity and specificity.
3 Results
The screening test results showed that the NMP 22
test had the highest sensitivity (Table 1). Cytology had
the highest specificity. The specificity of BTA TRAK
was similar to that of NMP 22 (Table 1). The sensitivity
of both BTA TRAK and NMP 22 increased with bladder
tumor grade (Table 2). In BTA TRAK immunoassay, the
sensitivity for grade II bladder tumor was 60% (Table 2).
The BTA TRAK level did not increase with bladder
cancer grading (Figure 1), however the level of NMP 22
increased with bladder tumor grading. The sample sizes
of tumor grading for the BTA TRAK screening test were
16 for grade I, 14 for grade II and 15 for grade III,
respectively. In contrast, the sample sizes for NMP 22
were 17, 16 and 15, respectively. The two screening
tests were performed by two doctors. The specificity
of cytology was clearly superior to that of the BTA TRAK
assay. The NMP 22 immunoassay showed that the higher
the grade of tumor, the higher the value of NMP 22
(Figure 2). Tukey_Krammer multiple comparison tests
showed that the difference between the low grade (grade
I) and high grades (grades II and III) was statistically
significant (P < 0.05). Among the different groups of
patients, bladder cancer had the highest NMP 22 and
BTA TRAK levels (Figures 3 and 4). The NMP 22 kit
test results for the benign lesions were less than the
cut-off value of 10 U/mL (Figure 3). The BTA TRAK kit
test results for benign lesions were greater than the
cut-off value of 14 U/mL (Figure 4).
4 Discussion
Many institutions routinely use screening cystoscopy,
urine cytology and random bladder biopsy to find
preclinical bladder cancer in elderly patients. Considerable
efforts have been made to improve the ability of
urologists to detect bladder cancer. Urine cytology is the gold
standard for non-invasive bladder cancer examination;
however, cytologists might not be available in all hospitals.
Furthermore, the cytological approach requires training
to achieve low sensitivity evaluation and results for
superficial tumors [9]. Some tumor markers have been
proposed for the detection of bladder tumors, but each
test has its drawbacks and limitations. The present study
assessed the accuracy of non-invasive tests for
detection of bladder cancer. Our analytical results show that
NMP 22 is superior to all other tests in overall accuracy.
The result is the same as that reported by Sözen
et al. [10]. Although the sensitivity of the NMP 22 test is higher
than that of the BTA TRAK test kit, a 1-day period is
required for the results from the NMP 22 test kit. The
BTA TRAK assay is a one-step test performed in 5 min
with a high sensitivity (57%_83%) [11_14]. Both NMP
22 and BTA TRAK tests are better than VUC for
detecting bladder cancer but have significantly low specificity.
These results are similar to those reported by Poulakis
et al. [14]. The NMP 22 test identified a significant
difference in sensitivity between patients compared with
the BTA TRAK test and cytology. The higher the tumor
grade, the higher the sensitivity for NMP22 and BTA
TRAK. Sözen et al.
[10] also found that NMP 22 and BTA TRAK consistently showed superior sensitivities to
VUC. There were also significant differences in degree
of differentiation: sensitivities of BTA TRAK and NMP
22 tests were higher in undifferentiated tumors [9,
15_17] in contrast to other studies [18, 19].
These differing results could be attributed to the different thresholds used
in these studies and differences in the number of patients
in each series. These differences might also be
attributed to the well-known difficulty in grading tumors [20].
Acceptable specificity and sensitivity of a test depends
on its clinical utility, associated intervention and patient-
care costs. Tests are useful in a clinical situation if they
have a significantly high sensitivity and specificity.
Required degrees of sensitivity and specificity also depend
on the prevalence of the disease, whether an elderly
patient is being screened for the first time, or evaluated for
recurrence. If the objective is to ensure an elderly
patient from disease and to avoid diagnostic cystoscopy, a
test with a high specificity and negative predictive value
is the most suitable to ensure that tumor is not missed.
However, if the goal is to use cystoscopy to detect
hematuria in an elderly patient, the sensitivity and positive
predictive value must be high enough to assure no
clinically relevant tumors are missed. The future risk of
developing bladder cancer developted in elderly patients
when a biomarker is expressed during carcinogenesis.
Biomarkers expressed early in carcinogenesis will have a
poor specificity but might indicate that a patient requires
close follow-up in case of clinical recurrence.
The incidence of bladder cancer in patients,
especially in aging men, has increased [2]. Those screening
programs have not been well established for detecting
bladder cancer in elderly patients. The present study
analyzed the application of biomarkers, as an adjunct or
a supplant to cystoscopy, as a screening test for bladder
cancer in elderly patients, and demonstrated that BTA
TRAK and NMP 22 are simple and convenient tests for
screening bladder cancer. Although neither test can
replace invasive cystoscopy, they provide extra
information about bladder cancer status. Both BTA TRAK and
NMP 22 tests can contribute significantly to bladder
tumor diagnoses as an adjunct to cystoscopy. Although
photodynamic diagnosis is another option for screening
bladder cancer, some kinds of photosensitizers have to
be introduced to the bladder, which means that the test
is not as convenient as NMP 22 or BTA TRAK [20]. Separation of inflammatory urothelial cells from
malignant variations is more reliable by cytology than with
either NMP 22 or BTA TRAK tests. The combination of
NMP 22, BTA TRAK and VUC can improve the diagnosis of bladder cancer. However, this combination
involves an increase in cost. The use of one or several
urinary diagnostic tests to reduce the frequency of
cystoscopic follow-up for elderly patients with bladder
cancer remains an interesting concept worthy of
prospective evaluation.
Acknowledgment
The authors would like to thank the Chang Gung Memorial Hospital (Contract No. CMRPG1006) for
financially supporting this research.
References
1 Lee SH, Chang PL, Chen SM, Sun GH, Chen CL, Shen BY,
et al. Synchronous primary carcinomas of the bladder and prostate.
Asian J Androl 2006; 8: 357_9.
2 Boring CC, Squires TS, Tong T. Cancer statistics, 1993. CA
Cancer J Clin 1993; 43: 7_26.
3 Ishizuka O, Mizusawa H, Nishizawa O. Roles of
dopaminergic receptors in bladder and erectile function at the spinal level.
Asian J Androl 2002; 4: 287_90.
4 Ellis WJ, Blumenstein BA, Ishak LM, Enfield DL. Clinical
evaluation of the BTA TRAK assay and comparison to voided
urine cytology and the Bard BTA test in patients with
recurrent bladder tumors. The Multi Center Study Group. Urology
1997; 50: 882_7.
5 Getzenberg RH, Konety BR, Oeler TA, Quigley MM, Hakam
A, Becich MJ, et al. Bladder cancer-associated nuclear matrix
proteins. Cancer Res 1996; 56: 1690_4.
6 Heicappell R, Wettig IC, Schostak M, Muller M, Steiner U,
Sauter T, et al. Quantitative detection of human complement
factor H-related protein in transitional cell carcinoma of
urinary bladder. Eur Urol 1999; 35: 81_7.
7 Getzenberg RH. Nuclear matrix and the regulation of gene
expression: tissue specificity. J Cell Biochem 1994; 55:
22_31.
8 Collan Y, Makinen J, Heikkinen A. Histological grading of
transitional cell tumours of the bladder. Value of histological
grading (WHO) in prognosis. Eur Urol 1979; 5: 311_8.
9 Giella JG, Ring K, Olsson CA, Karp FS, Benson MC. The
predictive value of flow cytometry and urinary cytology in
the followup of patients with transitional cell carcinoma of the
bladder. J Urol 1992; 148: 293_6.
10 Sozen S, Biri H, Sinik Z, Kupeli B, Alkibay T, Bozkirli I.
Comparison of the nuclear matrix protein 22 with voided urine
cytology and BTA stat test in the diagnosis of transitional cell
carcinoma of the bladder. Eur Urol 1999; 36: 225_9.
11 Wiener HG, Mian C, Haitel A, Pycha A, Schatzl G, Marberger
M. Can urine bound diagnostic tests replace cystoscopy in
the management of bladder cancer? J Urol 1998; 159:1876_80.
12 Leyh H, Marberger M, Conort P, Sternberg C, Pansadoro V,
Pagano F, et al. Comparison of the BTA stat test with voided
urine cytology and bladder wash cytology in the diagnosis and
monitoring of bladder cancer. Eur Urol 1999; 35: 52_6.
13 Pode D, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I.
Noninvasive detection of bladder cancer with BTA stat test. J
Urol 1999; 161: 443_6.
14 Poulakis V, Witzsch U, De Vries R, Altmannsberger HM,
Manyak MJ, Becht E. A comparison of urinary nuclear matrix
protein-22 and bladder tumour antigen tests with voided
urinary cytology in detecting and following bladder cancer: the
prognostic value of false-positive results. BJU Int 2001; 88:
692_701.
15 Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, Willset
LW, Dinney CP, Grossman HB, et al. Evaluation of NMP 22
in the detection of transitional cell carcinoma of the bladder. J
Urol 1998; 159: 394_8.
16 Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC.
Sensitivity and Specificity of NMP-22, telomerase, and BTA in the
detection of human bladder cancer. Urology 1998; 52:
398_402.
17 Carpinito GA, Stadler WM, Briggman JV, Chodak GW,
Church PA, Lamm DL, et al. Urinary nuclear matrix protein as
a marker for transitional cell carcinoma of the urinary tract. J
Urol 1996; 156: 1280_5.
18 Miyanaga N, Akaza H, Ishikawa S, Ohtani M, Noguchi R,
Kawai K, et al. Clinical evaluation of nuclear matrix protein
22(NMP22) in urine as a novel marker for urothelial cancer. Eur
Urol 1997; 31: 163_8.
19 Ooms EC, Anderson WA, Alons CL, Boon ME, Veldhuizen
RW. Analysis of the performance of pathologists in the
grading of bladder tumors. Hum Pathol 1983; 14: 140_3.
20 Sim HG, Lau WK, Olivo M, Tan PH, Cheng CW. Is
photodynamic diagnosis using hypericin better than white-light
cystoscopy for detecting superficial bladder carcinoma? BJU Int
2005; 95: 1215_8.
|